Navigation Links
OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib
Date:3/18/2008

-Second Issued Patent for Bevasiranib Broadly Covers siRNA Targeting of VEGF Expression, Further Strengthening OPKO's RNAi Intellectual Property

Portfolio-

MIAMI, March 18 /PRNewswire-FirstCall/ -- OPKO Health, Inc. (Amex: OPK) today announced that it has been issued a key patent by the United States Patent and Trademark Office (USPTO) for methods related to the use and administration of small interfering RNAs (siRNAs) for targeting vascular endothelial growth factor (VEGF), including OPKO's siRNA drug candidate, bevasiranib, which is currently in a Phase III trial for the treatment of wet age-related macular degeneration (AMD).

The claims of the newly issued patent cover a broad range of methods for the use of a specific sequence of siRNA, including bevasiranib, to target VEGF. The patent also covers application of this specific sequence of siRNA to inhibit the expression of VEGF and to treat VEGF-related angiogenic disorders including age-related macular degeneration, diabetic retinopathy and cancer. In addition, the claims cover any methods of administering the siRNA, including intravenous administration, retinal injections and oral administration. This newly issued patent broadly protecting the applications of OPKO's siRNA bevasiranib is the second for the compound. In late 2006, the USPTO issued a patent covering bevasiranib's composition of matter.

"This patent marks another important step in establishing OPKO's leadership position in the promising field of siRNA-based therapeutics," said Samuel Reich, Executive Vice President of OPKO Ophthalmics. "Bevasiranib was the first siRNA to enter human trials, the first siRNA to demonstrate clinically relevant activity in patients, the
'/>"/>

SOURCE OPKO Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
3. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
8. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
9. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
10. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
11. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... -- According to a new market research report, ... (2015-2020), , published by Mordor Intelligence, the Global market is ... of 2020, with North America being ... the global market size. The Global market for Stem Cells ... the period of (2015-2020).      (Logo: http://photos.prnewswire.com/prnh/20150428/740799) , ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... the Company,s Chief Financial Officer has resigned.  The Company ... Financial Officer who retired in December 2014, as full ... a permanent successor.     Andy Ashworth ... and ensure a smooth transition.  Andy was the Company,s ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... manufacturer and supplier, announces the launch of their 2nd generation cell therapy POD® ... current miniPOD CT, but it also represents a new POD® design. , ...
(Date:7/29/2015)... , July 29, 2015  AmnioChor Inc., an early ... is very pleased to announce that the Musculoskeletal Transplant ... agreed to invest in their seed round of development ... tissue storage capabilities. AmnioChor,s technology allows ... the human stem cells living within those tissues. Amnion ...
Breaking Biology Technology:Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2
... Public Health and Safety is a major ... homes and everywhere in between, dangerous germs like MRSA and ... and more people are contracting various strains of bacteria and ... approximately 15 to 60 million people contract seasonal flu each ...
... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a ... announced that BioSpecifics, President, Tom Wegman, will present at ... on Wednesday, September 15, 2010, at 9:35am EDT. ... be accessed under "Calendar of Events" in the Investor ...
... FRANCISCO and ILLKIRCH, France, Sept. 8 Jennerex, ... the development and commercialization of first-in-class targeted oncolytic ... FR0005175080), a bio-pharmaceutical company specialized in the development ... entered into an exclusive partnership to develop and ...
Cached Biology Technology:SpectraSan 24 Holds First Public Health and Safety Symposium in Ohio 2SpectraSan 24 Holds First Public Health and Safety Symposium in Ohio 3Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers 2Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers 3Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers 4Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers 5
(Date:7/8/2015)... , N.J. and NEW YORK , July ... Guidepoint today announced BD & Guidepoint ... companies with free access to Guidepoint,s expert network services. ... that are developing cutting-edge technologies to improve healthcare delivery ... Guidepoint research manager, each start-up entrepreneur will be able ...
(Date:7/7/2015)... Conn. , July 7, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market announces a revised version ... this week. The commercial will air on CNBC in ... Los Angeles and San Francisco ... The commercial focuses on Wocket,s ability to replace all the cards ...
(Date:6/30/2015)... Pa. , June 30, 2015 ... the company as CEO to help further develop Genisphere,s ... wealth of partnering experience, having spent much of the ... including Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. ... focus on Technology and Biotech Corporate Finance. He graduated ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... Iowa State University researchers have developed a technology that ... cervical cancer in women. Thats a significant improvement ... Edward Yeung, an Iowa State Distinguished Professor and the ... research team that developed the new test. The current ...
... percent increase in lifespan, raising the tantalizing question of ... taking an anti-aging medication. Results of the Buck Institute ... are currently published online in the Journal of Biological ... mood affective disorders, including bipolar disease for decades. While ...
... Monmouth University,s Urban Coast Institute will host its ... 2007, from 10 a.m. to 12 p.m., in the ... an Ocean Literate Society: Building Communities for Action," will ... of communication will be used to increase the general ...
Cached Biology News:Iowa State researchers develop technology for early detection of viruses 2Drug commonly used to treat bipolar disorder dramatically increases lifespan in worms 2Abel to receive posthumous Ocean and Coastal Leadership award 2
... Thermo's Wellwash AC is the easiest ... and is provided with liquid level ... bottles. The integrated orbital shaker and ... excellent washing performance. The big bottle ...
... Labsystems' Wellwash AC is the ... washer available, and is provided ... wash, waste and rinse bottles. ... automatic rinsing and priming functions ...
The Wellwash 4 Mk 2 microplate washer combines flexibility, simplicity and ease of use. This reliable microplate washer meets the exacting standards of today's ELISA assay requirements....
... Rabbit polyclonal to MLF1 Interacting Protein/PBIP1 ... all tested applications). ... to amino acids 73-83 of Human ... Entrez Gene ID: 359815 ...
Biology Products: